Recent investigations have centered on the overlap of GLP|GIP|GCGR agonist therapies and DA communication. While GLP agonists are commonly employed for treating type 2 diabetes mellitus, their emerging consequences on reward circuits, specifically mediated by dopaminergic systems, are gaining significant focus. This report details a brief overvi… Read More